The RSVital Trial is evaluating an investigational vaccine, called mRNA-1345, to determine if it may provide additional protection against RSV in adults aged 60 and older when given as a revaccination.
Today’s vaccines protect against many strains of pneumococcal bacteria, but not all of them. We’re researching an investigational vaccine designed to potentially help expand protection against more bacterial strains and possibly improve the body’s immune response to further reduce rates of infection.
The Duo P201 Trial Part 2 will evaluate the safety and immune response of 2 batches of an investigational combination vaccine aimed at preventing both seasonal flu and COVID-19 infections in adults 50 to 64 years of age.
Learn more about Pfizer’s research study for an investigational COVID-19 and flu combination vaccine.
Indago delivers community-based services for Miami and neighboring areas, driving advances in investigational research for new and improved drugs.
Working Hours
Monday-Friday 8:00 AM – 5:00 PM
Saturday (open if necessary)
Sunday (open if necessary)